Xiaobin Wu - BGNE Old President COO
President
Dr. Xiaobin Wu is General Manager, China and President of the Company. He joined our Company in April 2018 as our General Manager, China and President. He has more than 25 years of experience in the pharmaceutical industry, including 17 years leading China operations of multinational companies, with expertise in research and development, strategy, commercialization and general management. Before joining the Company in April 2018, Dr. Wu served as the Country Manager of Pfizer China from 2009 to April 2018 and Regional President of Pfizer Essential Health in the Greater China Region from 2017 to April 2018. Under his leadership, Pfizer China experienced significant growth to become a leading multinational pharmaceutical company in China. Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong from 2004 to 2009. Before joining Wyeth, Dr. Wu served as the General Manager of Bayer Healthcare in China from 2001 to 2004. He started his career in 1992 in sales and marketing with Bayer in Germany since 2018.
| Age | 63 |
| Tenure | 7 years |
| Phone | 345-949-4123 |
| Web | https://www.beigene.com |
Xiaobin Wu Latest Insider Activity
Tracking and analyzing the buying and selling activities of Xiaobin Wu against BGNE Old stock is an integral part of due diligence when investing in BGNE Old. Xiaobin Wu insider activity provides valuable insight into whether BGNE Old is net buyers or sellers over its current business cycle. Note, BGNE Old insiders must abide by specific rules, including filing SEC forms every time they buy or sell BGNE Old'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Xiaobin Wu over two months ago Disposition of tradable shares by Xiaobin Wu of BeiGene subject to Rule 16b-3 | ||
Xiaobin Wu over a year ago BeiGene exotic insider transaction detected | ||
Xiaobin Wu over a year ago Acquisition by Xiaobin Wu of 200447 shares of BeiGene subject to Rule 16b-3 | ||
Xiaobin Wu over a year ago BeiGene exotic insider transaction detected |
BGNE Old Management Efficiency
The company has return on total asset (ROA) of (0.0958) % which means that it has lost $0.0958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2322) %, meaning that it created substantial loss on money invested by shareholders. BGNE Old's management efficiency ratios could be used to measure how well BGNE Old manages its routine affairs as well as how well it operates its assets and liabilities.BGNE Old currently holds 930.18 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. BGNE Old has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BGNE Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Andrew MBA | Vaxcyte | 57 | |
| Fouad MD | Blueprint Medicines Corp | 56 | |
| Suma Krishnan | Krystal Biotech | 60 | |
| Dashyant Dhanak | Incyte | 63 | |
| Victoria Brown | Apellis Pharmaceuticals | 45 | |
| Flemming Jensen | Ascendis Pharma AS | 64 | |
| Frank Bennett | Ionis Pharmaceuticals | 67 | |
| Wade Walke | Ionis Pharmaceuticals | N/A | |
| Scott Smith | Ascendis Pharma AS | 51 | |
| Christopher Murray | Blueprint Medicines Corp | 61 | |
| Guowei Fang | Legend Biotech Corp | N/A | |
| Meredith Kaya | Apellis Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.23 | |||
| Return On Asset | -0.0958 |
BGNE Old Leadership Team
Elected by the shareholders, the BGNE Old's board of directors comprises two types of representatives: BGNE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BGNE. The board's role is to monitor BGNE Old's management team and ensure that shareholders' interests are well served. BGNE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BGNE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaodong Wang, CoChairman CoFounder | ||
| John Oyler, Chairman of the Board, CEO, Founder | ||
| Mi Zhou, Director Relations | ||
| Liza Heapes, Head Relations | ||
| Chan Lee, General VP | ||
| Wang Lai, Global RD | ||
| Kevin Mannix, VP Relations | ||
| Titus Ball, VP Officer | ||
| Julia Wang, Executive Officer | ||
| Aaron Rosenberg, CFO Officer | ||
| Jason Radford, Senior Development | ||
| Yang Ji, Chief Officer | ||
| Daniel Maller, VP Accounting | ||
| Jaspreet MD, Senior Strategy | ||
| Diana Francis, VP Compliance | ||
| Melika Davis, Clinical Head | ||
| Yan Qi, Senior China | ||
| Xiaobin Wu, President COO |
BGNE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BGNE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | |||
| Return On Asset | -0.0958 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.14) % | |||
| Current Valuation | 18.78 B | |||
| Shares Outstanding | 97.63 M | |||
| Shares Owned By Insiders | 19.43 % | |||
| Shares Owned By Institutions | 46.90 % | |||
| Number Of Shares Shorted | 1.38 M | |||
| Price To Earning | (16.19) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in BGNE Stock
If you are still planning to invest in BGNE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BGNE Old's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |